(Q38029543)

27 August 2017

Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes (English)

1 reference

27 August 2017

5

Federico Garrido

1 reference

27 August 2017

Monica Bernal

1

1 reference

27 August 2017

Francisco Ruiz-Cabello

series ordinal

2

1 reference

27 August 2017

Angel Concha

series ordinal

3

1 reference

27 August 2017

Annette Paschen

series ordinal

4

1 reference

27 August 2017

language of work or name

1 reference

26 July 2012

1 reference

Cancer Immunology, Immunotherapy

27 August 2017

1 reference

27 August 2017

61

1 reference

27 August 2017

1359-1371

1 reference

27 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-012-1321-6

27 August 2017

0 references

cites work

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

The immunologic constant of rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Targeting HLA class I expression to increase tumor immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

A new beta 2 microglobulin mutation found in a melanoma tumor cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Mechanisms of loss of HLA class I expression on colorectal tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

DNA-replication fidelity, mismatch repair and genome instability in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2‐microglobulin inactivation in MSI‐positive tumors and LMP7/TAP2 downregulation in MSI‐negative tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta2-microglobulin genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Allele loss on chromosome 11q and microsatellite instability in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Genetic pathways to melanoma tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Molecular mechanisms of antibody somatic hypermutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Activation-induced cytidine deaminase expression in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Aberrant AID expression and human cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Molecular mechanism for generation of antibody memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Mechanisms of immune evasion by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

IFN inducibility of major histocompatibility antigens in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

SelTarbase, a database of human mononucleotide-microsatellite mutations and their potential impact to tumorigenesis and immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Efficient recovery of HLA class I expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

A weakly tumorigenic phenotype with high MHC class-I expression is associated with high metastatic potential after surgical removal of the primary murine fibrosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

HLA expression in uveal melanoma: there is no rule without some exception

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Structural and functional analysis of beta2 microglobulin abnormalities in human lung and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

MUTYH-associated polyposis carcinomas frequently lose HLA class I expression - a common event amongst DNA-repair-deficient colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1321-6

10.1007/S00262-012-1321-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

0 references

1 reference